血管免疫母细胞性T细胞淋巴瘤继发急性髓系白血病三例并文献复习  

Acute myeloid leukemia secondary to angioimmunoblastic T-cell lymphoma： report of three cases and review of literature

作　　者：商豫凤 付晓瑞[1] 张蕾[1] 南飞飞[1] 张明智[1] 王新华[1] Shang Yufeng, Fu Xiaorui, Zhang Lei, Nan Feifei, Zhang Mingzhi, Wang Xinhua(Deportment of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450002, Chin)

机构地区：[1]郑州大学第一附属医院肿瘤科,450002

出　　处：《白血病．淋巴瘤》2018年第3期164-167,共4页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金（81570203）;河南省基础与前沿技术研究计划（142300410325）

摘　　要：目的 探讨血管免疫母细胞性T细胞淋巴瘤（AITL）继发急性髓系白血病（AML）的临床特征、发病机制、诊断、治疗及预后。方法 回顾性分析3例AITL继发AML患者的临床资料，包括免疫组织化学、流式细胞术结果，并进行文献复习。结果 3例均为老年男性患者，初诊为AITL，分别于治疗后的8、14及34个月继发AML。继发AML后，1例未治疗于10个月后死亡，1例积极治疗后于13个月后死亡，另1例失访。结论 AITL有继发AML的风险，其发病机制目前尚不清楚，预后较差。Objective To investigate the clinical characteristics, pathogenesis, diagnosis, treatment and prognosis of acute myeloid leukemia secondary to angioimmunoblastic T-cell lymphoma.Methods The clinical data of 3 patients with acute myeloid leukemia secondary to angioimmunoblastic T-cell lymphoma including immunohistochemistry and flow cytometer analysis were analyzed retrospectively, then the literature was reviewed.Results All the 3 patients were elderly men and the initial diagnosis was angioimmunoblastic T-cell lymphoma. The 3 cases developed secondary acute myeloid leukemia in 8 months, 14 months and 34 months after treating primary neoplasms respectively. After diagnosed acute myeloid leukemia, one case died 10 months later without treatment, one case died 13 months later despite aggressive treatment and one case lost follow-up.Conclusion Angioimmunoblastic T-cell lymphoma has risk to developing acute myeloid leukemia, and there is a poor survival and the pathogenesis is unclear.

关 键 词：血管免疫母性T细胞淋巴瘤 白血病 髓样 急性 继发肿瘤 发病机制 预后 

分 类 号：R733.71[医药卫生—肿瘤]